Overcoming intractable diseases
with regeneration-inducing medicine

StemRIM is a biotechnology company aiming to develop a next generation of regenerative medicine,
"Regeneration-inducing Medicine".

Overcoming intractable diseases
with regeneration-inducing medicine

StemRIM is a biotechnology company aiming to develop a next generation of regenerative medicine,
"Regeneration-inducing Medicine".

IR News

June 01, 2023 IR News StemRIM Announces Exhibiting at the “BIO International Convention 2023” and Participating in the “Jefferies 2023 Global Healthcare Conference New York” 
May 24, 2023 IR News StemRIM Announces Orphan Drug Designation of Regeneration-Inducing Medicine Redasemtide (HMGB1 peptide) 
May 22, 2023 IR News StemRIM Announces Results from Phase 2 Clinical Trial of Redasemtide in Patients with Chronic Liver Disease (Additional Report) 
May 19, 2023 IR News [Delayed]StemRIM Announces Patent Registration (Taiwan) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Therapeutic Indication for Cardiomyopathy and Old Myocardial Infarction 
May 16, 2023 IR News StemRIM Announces Publication of Scientific Articles for Stem Cell Gene Therapy (PJ5) 
IR News Here

NEWS Release

April 25, 2023 NEWS Release
News Release Here

Video

Video Here

We aim to bring a happy future to patients suffering from intractable diseases.

StemRIM is a biotechnology company aiming to develop a next generation of regenerative medicine, "Regeneration-inducing Medicine".
"Regeneration-inducing Medicine" is an innovative new class of medicine that induces functional regeneration of tissues and organs in the patient's body by maximizing the human body's innate ability of tissue repairing.
We are pursuing research and development of new drugs based on a novel mechanism of action leading to recruitment of the patients’ own in-vivo stem cells to the damaged tissues for functional tissue regeneration without conventional cell-therapy approaches.

What is Regeneration-inducing
Medicine?
Issues of Conventional
Cell Therapy
The Superiority of
Regeneration-Inducing Medicine

Business

Corporate Information Investor Relations